Post hoc analysis of 242 placebo-treated patients with severe COVID-19 in the OSCAR trial: high day-1 serum PRO-C3 and PRO-C6 (fibroblast activity markers) were associated with higher mortality (HR 2.93 and 3.88), with levels rising sharply before death.
Secondary analysisn = 242
Breisnes et al. Fibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trial